Liquidia Technologies (LQDA)
(Delayed Data from NSDQ)
$12.87 USD
+0.01 (0.08%)
Updated May 31, 2024 04:00 PM ET
After-Market: $14.46 +1.59 (12.35%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
Liquidia Technologies, Inc. [LQDA]
Reports for Purchase
Showing records 101 - 120 ( 128 total )
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
LIQ861/PAH: NDA Submitted; We Anticipate NDA Acceptance for Review in Q1
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Q3: Near-Term Financing Likely but Potentially Nondilutive; LIQ861 NDA in Q1:20
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
No Additional CMC Requirements for LIQ861/PAH NDA; Filing by Early Q1:20
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials - Pipeline Progress; LIQ861/PAH NDA Filing by YE
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Restructuring of GSK Partnership Provides Opportunity for Pipeline Expansion
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Pre-NDA Meeting in Q4 - Potential NDA Submission by YE
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; On-track to Submit LIQ865/PAH NDA by YE
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Positive Functional and Quality of Life Results for LIQ861 at ISHLT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Cash Runway Covers Multiple Potential Catalysts in 2019/2020; Time to Buy
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D